• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.

作者信息

Bjornsson Aron Hjalti, Grondal Gerdur, Kristjansson Mar, Jonsdottir Thorunn, Love Thorvardur Jon, Gudbjornsson Bjorn

机构信息

Medicine, National University Hospital of Iceland, Reykjavik, Iceland

Faculty of Medicine, University of Iceland School of Health Sciences, Reykjavik, Iceland.

出版信息

Ann Rheum Dis. 2021 May;80(5):671-672. doi: 10.1136/annrheumdis-2020-219564. Epub 2021 Jan 5.

DOI:10.1136/annrheumdis-2020-219564
PMID:33402343
Abstract
摘要

相似文献

1
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.使用靶向合成或生物改善病情抗风湿药物或甲氨蝶呤治疗的风湿性疾病患者中新冠病毒病的患病率、入院率及缺氧情况：冰岛的一项全国性研究
Ann Rheum Dis. 2021 May;80(5):671-672. doi: 10.1136/annrheumdis-2020-219564. Epub 2021 Jan 5.
2
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.COVID-19 在接受靶向生物制剂和合成疾病修饰抗风湿药物治疗的成人和儿科风湿性疾病患者队列中的发病率。
Semin Arthritis Rheum. 2020 Aug;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001. Epub 2020 May 16.
3
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini .风湿性疾病患者中新型冠状病毒肺炎（COVID-19）的患病率：需要等待大型合作研究的结果。对Conticini所著《一大群接受生物和靶向合成抗风湿药物治疗的患者中的COVID-19肺炎》的回应
Ann Rheum Dis. 2021 Feb;80(2):e15. doi: 10.1136/annrheumdis-2020-217738. Epub 2020 May 15.
4
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.COVID-19 相关住院风险因素在自身免疫性炎症性风湿病患者中的分析。
Ann Rheum Dis. 2020 Nov;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984. Epub 2020 Aug 7.
5
Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.炎症性风湿病患者在使用疾病修正抗风湿药物治疗的情况下对 SARS-CoV-2 疫苗接种的血清学反应：一项队列研究和荟萃分析。
Joint Bone Spine. 2022 Oct;89(5):105380. doi: 10.1016/j.jbspin.2022.105380. Epub 2022 Apr 28.
6
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.接受生物和合成靶向治疗的风湿性疾病患者中COVID-19的临床特征和结局
Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
7
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.慢性炎症和自身免疫性风湿病患者中经医院聚合酶链反应（PCR）确诊的 COVID-19 病例的流行情况。
Ann Rheum Dis. 2020 Sep;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763. Epub 2020 Jun 12.
8
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
9
Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases.区域性儿童风湿性疾病患者队列的临床特征和 COVID-19 结局。
Pediatr Rheumatol Online J. 2021 Nov 27;19(1):162. doi: 10.1186/s12969-021-00648-5.
10
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?COVID-19 疫情期间的风湿性疾病生物制剂：是敌是友？
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001439.

引用本文的文献

1
COVID-19 infection and efficacy of vaccination in patients with rheumatic diseases during Omicron outbreak in South Korea: a prospective cohort study.韩国奥密克戎疫情期间风湿性疾病患者的 COVID-19 感染和疫苗效力：一项前瞻性队列研究。
RMD Open. 2023 Nov;9(4). doi: 10.1136/rmdopen-2023-003398.
2
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.专家共识：影响 COVID-19 预后不良的主要危险因素及其对靶向 SARS-CoV-2 措施的影响。
Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.
3
Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study.
系统性风湿病患者的 COVID-19 结局差异：一项全国性队列研究。
Rheumatology (Oxford). 2023 Mar 1;62(3):1047-1056. doi: 10.1093/rheumatology/keac422.
4
COVID-19 outcomes in patients with cancer: Findings from the University of California health system database.癌症患者的 COVID-19 结局：来自加利福尼亚大学健康系统数据库的研究结果。
Cancer Med. 2022 Jun;11(11):2204-2215. doi: 10.1002/cam4.4604. Epub 2022 Mar 9.
5
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.靶向治疗在 COVID-19 结局中的风湿患者中的作用：COVIDSER 研究结果。
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001925.